Browse by author
Lookup NU author(s): Emeritus Professor Greg RubinORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Much time, effort and investment goes into the diagnosis of symptomatic cancer, with the expectation that this approach brings clinical benefits. This investment of resources has been particularly noticeable in the UK, which has, for several years, appeared near the bottom of international league tables for cancer survival in economically developed countries. In this Review, we examine expedited diagnosis of cancer from four perspectives. The first relates to the potential for clinical benefits of expedited diagnosis of symptomatic cancer. Limited evidence from clinical trials is available, but the considerable observational evidence suggests benefits can be obtained from this approach. The second perspective considers how expedited diagnosis can be achieved. We concentrate on data from the UK, where extensive awareness campaigns have been conducted, and initiatives in the primary-care setting, including clinical decision support, have all occurred during a period of considerable national policy change. The third section considers the most appropriate patients for cancer investigations, and the possible community settings for identification of such patients; UK national guidance for selection of patients for investigation is discussed. Finally, the health economics of expedited diagnosis are reviewed, although few studies provide definitive evidence on this topic.
Author(s): Hamilton W, Walter FM, Rubin G, Neal RD
Publication type: Review
Publication status: Published
Journal: Nature Reviews Clinical Oncology
Print publication date: 01/12/2016
Online publication date: 26/07/2016
Acceptance date: 02/04/2016
ISSN (print): 1759-4774
ISSN (electronic): 1759-4782
Publisher: Nature Publishing Group
PubMed id: 27458007